Ankur Dhingra - Illumina Chief Officer
| ILMN Stock | USD 108.10 0.97 0.89% |
Executive
Ankur Dhingra is Chief Officer of Illumina
| Age | 48 |
| Address | 5200 Illumina Way, San Diego, CA, United States, 92122 |
| Phone | 858 202 4500 |
| Web | https://www.illumina.com |
Ankur Dhingra Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ankur Dhingra against Illumina stock is an integral part of due diligence when investing in Illumina. Ankur Dhingra insider activity provides valuable insight into whether Illumina is net buyers or sellers over its current business cycle. Note, Illumina insiders must abide by specific rules, including filing SEC forms every time they buy or sell Illumina'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ankur Dhingra over a year ago Purchase by Ankur Dhingra of 13027 shares of Summit Therapeutics |
Illumina Management Efficiency
As of the 20th of June 2024, Return On Tangible Assets is likely to grow to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.0086. At this time, Illumina's Debt To Assets are very stable compared to the past year. As of the 20th of June 2024, Fixed Asset Turnover is likely to grow to 3.35, while Non Currrent Assets Other are likely to drop about 123.4 M. Illumina's management efficiency ratios could be used to measure how well Illumina manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marney Kadrmas | Knife River | 54 | |
| Jay Hohauser | Aeye Inc | N/A | |
| Matthew Blickley | Coca Cola Consolidated | 41 | |
| Heath Attia | Aeye Inc | N/A | |
| Amy Cianciaruso | Charles River Laboratories | N/A | |
| Brenda Carrillo | Aeye Inc | N/A | |
| Donell Etheridge | Coca Cola Consolidated | 54 | |
| Mark Mintz | Charles River Laboratories | N/A | |
| Jeff Lambert | Knife River | N/A | |
| Andrew Hughes | Aeye Inc | 58 | |
| Tony Spilde | Knife River | N/A | |
| Jeremy Stover | Knife River | N/A | |
| Nancy Christenson | Knife River | 67 | |
| Christine Motherwell | Coca Cola Consolidated | 45 | |
| Pr Frearson | Charles River Laboratories | N/A | |
| Andy Cramer | Knife River | N/A | |
| Nathaniel Tollison | Coca Cola Consolidated | 50 | |
| Todd Spencer | Charles River Laboratories | N/A | |
| Erica Allen | Aeye Inc | N/A | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.005 |
Illumina Leadership Team
Elected by the shareholders, the Illumina's board of directors comprises two types of representatives: Illumina inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Illumina. The board's role is to monitor Illumina's management team and ensure that shareholders' interests are well served. Illumina's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Illumina's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Ericksen, VP Officer | ||
| Kevin Pegels, Chief Operations | ||
| Charles Esq, Senior Counsel | ||
| Joydeep MBA, Executive Officer | ||
| Sharon Vidal, Global Responsibility | ||
| Steven Hoffman, Segment Sequencing | ||
| Bas Verhoef, Interim RegionEurope | ||
| Sallilyn Schwartz, Vice Relations | ||
| Francis deSouza, Pres and Director | ||
| Jacob Thaysen, CEO Director | ||
| Susan Tousi, Chief Officer | ||
| Pat Leckman, Interim Officer | ||
| Charles Dadswell, Senior Vice President General Counsel, Secretary | ||
| Kathryne Reeves, Chief Officer | ||
| Ankur Dhingra, Chief Officer | ||
| Nicole Berry, Head RegionAmericas | ||
| Steven Barnard, Chief Officer | ||
| Alexander MD, CTO Devel | ||
| Stephanie Campos, President | ||
| Carissa Rollins, Chief Officer | ||
| Jenny Zheng, Head China | ||
| Gretchen Weightman, Middle Pacific | ||
| Mena Farag, Senior Specialist |
Illumina Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Illumina a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.005 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 18.39 B | ||||
| Shares Outstanding | 159.3 M | ||||
| Shares Owned By Insiders | 0.26 % | ||||
| Shares Owned By Institutions | 95.00 % | ||||
| Number Of Shares Shorted | 5.82 M | ||||
| Price To Earning | 49.12 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Illumina Stock
When determining whether Illumina offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Illumina's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Illumina Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Illumina Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (8.15) | Revenue Per Share 28.392 | Quarterly Revenue Growth (0.01) | Return On Assets (0.01) |
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.